Document is current
Any future updates will be listed below
-
Authors
Cinque, Francesco
van den Tillaert, Femke M
Yzer, Suzanne
de Breuk, Anita
Heesterbeek, Tom J
Hoyng, Carel B
Lechanteur, Yara TE https://orcid.org/0000-0003-0951-4625
-
Funding
Funding for this research was provided by:
Bayer (BHC-RD-SOP-038)
Landelijke Stichting voor Blinden en Slechtzienden (Uitzicht-2021-32)
Algemene Nederlandse Vereniging ter voorkoming van Blindheid (Uitzicht-2021-32)
Stichting Beheer Het Schild via Steunfonds Uitzicht (Uitzicht-2021-32)
Oogfonds (Uitzicht-2021-32)
- License Information
-
More Information
Article History
Received: 29 September 2024
Revised: 11 December 2024
Accepted: 14 January 2025
First Online: 8 March 2025
Declarations
:
: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Medisch-Ethische Commissie Oost-Nederland and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
